RCaz/eu-funding-proposals-sft huggingface dataset:
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'Development and application of fine-mapping methods for the study of ETL in cattle' demonstrating excellence, impact and implementation quality for a Fourth Framework call.

assistant: **Abstract**

BOREALIS aims to develop the resources and methodology required for genetic and physical fine-mapping of Economic Trait Loci (ETL) in cattle, a fundamental prerequisite to allow their efficient use in Marker Assisted Selection programs. The proposal is divided in four interrelated Work Packages. Work Page 1 comprises the construction of bovine large-fragment DNA libraries in YAC and PAC vectors. Both libraries will be characterised for average insert size, genome coverage and degree of chimerism. Both libraries will be stored, handled and distributed via the Reference Library Database. Each library will be freely available on request, to the scientific community. Work package 2 comprises the development of Comparative Mapping of Anonymous Exons". The objective is to determine the homologous locus on the human gene map of an ETL of interest in cattle. The strategy is based on the predicted cross-hybridization between anonymous exons contained in bovine large insert clones isolated with microsatellite markers shown to be linked to the trait of interest. Three alternative approaches will be evaluated in a trial experiment involving wellcharacterised loci: CFTR and MHC. The most efficient method will then be applied to three specific ETL: MH, Polled and a QTL for milk production. The identification of the human homologous locus will allow the use of neighbouring human ESTs as a source of candidate genes and as conserved STSs for contig construction in cattle. Work Package 3 consists in the generation of additional STSs specific for the three ETL of interest by chromosome-band microdissection and amplification. The chromosome-band carrying the ETL of interest will be identified by FISH using bovine large insert clones isolated with microsatellite markers linked to the trait
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write the concept and methodology overview for 'Phylogenetic ANalysis of Diversification Across the tree of life' under Seventh Framework.

assistant: **Concept**

Explaining the tremendous disparity in the number of species among different taxonomic groups and geographic regions is one of the greatest challenges in biodiversity research.  This project aims to significantly advance our fundamental understanding of the ecological and evolutionary processes that explain how species richness is distributed on earth and in the tree of life. The first part of the project consists in significantly improving phylogenetic approaches to diversification. This implies developing stochastic lineage-based birth-death models that account for species interactions, stochastic lineage-based birth-death models integrating phylogenetic and fossil information, and stochastic individual-based birth-death-speciation models. The second part of the project consists in implementing these models, as well as other recently developed models, in efficient and user-friendly software packages. Finally, the third part of the project consists in applying these phylogenetic tools to large datasets spanning the tree of life in order to understand how and why speciation and extinction rates vary over evolutionary time, geographical space, and species groups. We will use our new phylogenetic comparative methods to uncover diversity-through-time curves for a wide variety of taxonomic groups, evaluate the relative role of the biotic and the abiotic environment in driving diversification, shed new light on the latitudinal diversity gradient, and consider microbial diversity with a macroevolutionary perspective. The proposed research will provide the scientific community with novel, user-friendly modeling tools for understanding biodiversity, and will yield unprecedented insights into the dynamics and determinants of biodiversity.""
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft an impact statement for 'Impact characterisation of single end duplex surface engineered systems', explaining its relevance to EU policy priorities under Fourth Framework.

assistant: **Impact**

Although hardness measured by indentation techniques is a useful design parameter, it is inadequate in situations where a surface engineered system experiences repeated loading or impacting conditions in operation, e.g., cutting and forming tools. The proposed programme will involve the design, manufacture and evaluation of two types of novel indentation instruments for the property evaluation of various surface engineering systems. It is foreseen that demonstration instruments and associated control software will be outputs of the research. The prime industrial/economic objectives are: - To improve the reliability of surface engineered engineering components operating under impact conditions in manufacturing industry; - To increase the design awareness of the technical and economic benefits of single and duplex surface engineered systems. The RTD goals of the proposed programme are: - To develop a continuous load and depth recording instrument for the measurement of both coating adhesion and the load bearing capacity of surface engineered systems. - To develop a cyclic impact test machine for the evaluation of single and duplex surface engineered systems. - to structurally characterise a variety of surface engineered systems and correlate such data with their impact behaviour. - To simulate, model and develop software packages for the service behaviour of surface engineered systems under diverse impact loading conditions.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Explain how 'LUCERO BIO: Smart Optofluidic Isolation of Spheroids for Early-Stage Drug Discovery' goes beyond current state-of-the-art under Horizon Europe.

assistant: **Innovation**

Personalised medicine has become a key focus for the pharmaceutical industry as it can address global health challenges, such asstrong variations of drug efficacy and toxicity linked to different patient subgroups. A major obstacle that pharmaceutical companies still face is the lack of enabling technologies to predict the effects of drug candidates in patients before entering clinical trials. In preclinical drug screening procedures, pharmaceutical companies demand that the technologies be selective in terms of detection and isolation of patient-derived 3D cell cultures while being scalable for high-throughput drug screening. Lucero fills this need by providing a novel cell-handling platform that combines microfluidics, optical tweezers and artificial intelligence. During our ERC PoC project, we developed an integrated benchtop device for in-vitro handling of single 3D cell cultures, in particular mini spheroids. Lucero will build on this achievement by expanding our prototype’s functionalities and adapting its design to automatically detect spheroid viability and fully automate their isolation, to match the drug screening workflow. By thoroughly testing the prototype’s performance and compatibility with our large European pharmaceutical partner on-site, we will mature our prototype to technological readiness level (TRL) 6. Based on their feedback we will increase our commercial readiness level (CRL) 6 and will be ready for the next acceleration phase.The intended result of this proposal is to introduce Lucero’s 3D cell-handling platform as an enabling tool for pharmaceuticalcompanies to develop more effective “near-patient” treatments at a lower cost, as well as to establish Europe as a leader in precision healthcare.


**Keywords:** 3D Cell Culture, Spheroid, Neural
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Draft the 'Objectives and Scope' section of a Sixth Framework proposal for the project 'Identification and functional analysis of genes from mouse primordial germ cells that are implicated in the epigenetic reprogramming of the genome'.

assistant: **Objectives**

Development from a totipotent zygote into an adult occurs essentially without changes in DNA sequences but involves epigenetic mechanisms. This includes modifications of histones and DNA such as methylation, which regulate expression of specific set of genes present in all cells. Similar mechanisms are also involved during differentiation of pluri potent stem cells. These modifications are however reversible, for example, when somatic nuclei re-acquire totipotency when transplanted into oocytes. There is also an extensive erasure of most of the pre-existing epigenetic information in primordial germ cells (PGCs) immediately after their entry into the developing gonads, which provides a unique opportunity to discover the mechanism of epigenetic reprogramming of the genome. PGCs until about E10.5 possess modifications of the DNA that are similar to those in somatic cells, such as DNA methylation of specific regulatory elements, as well as the inactive X chromosome. However, when PGCs enter into the developing gonads, this information is erased, rapidly and substantially by E12.5.This process is prerequisite for subsequent totipotency of the zygote. I propose to identify and study the key genes involved in the erasure of epigenetic information from PGCs. PGCs will be isolated from genital ridges at E10 and from E11.5. Key candidate genes that are activated between E10.0 and E11.5 will be identified using Representational Difference Analysis (RDA) and micro-array analysis. Subsequently, verification of their expression patterns will be carried out by in situ hybridisation and real time RT-PCR on PGCs isolated from E9.5 to E12.5. Functional analysis of the candidates will involve cell-based assays in vitro, and siRNA in ES cells. These modified ES cells will be introduced int
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the specific objectives and expected outcomes for 'PHOS-SVD: PHOSpholipids in Cerebral Small Vessel Disease' in the context of a Horizon Europe call.

assistant: **Objectives**

Cerebral small vessel disease (SVD) is the leading cause of vascular dementia, plays a significant role in Alzheimer's disease and increases stroke risk, highlighting its critical impact on our ageing population. Endothelial cell dysfunction precedes other pathologies in both human SVD and preclinical models, where a causative deletion mutation and a single nucleotide polymorphism in the phospholipid flippase ATP11B were identified. However, the mechanism of action of ATP11B in SVD remains unclear. ATP11B is thought to mediate the translocation of phospholipids phosphatidylserine (PS) and phosphatidylethanolamine (PE) from the outer to the inner leaflet of plasmalemmal and intracellular vesicular organelle membranes. Both PS/PE contribute to membrane curvature and are essential for function of vesicular organelles. Single-nucleus transcriptome data from human SVD donors suggests involvement of lysosomal/autophagosomal pathways in SVD-affected endothelial cells, while loss of ATP11B disrupts membrane integrity, indicating that lipid changes drive SVD pathology.In PHOS-SVD, I hypothesize that loss of ATP11B alters the normal PS/PE lipid signature of endothelial cell membranes, altering lysosomal/autophagosomal function, promoting endothelial cell dysfunction and SVD pathology. Here, I will address 3 objectives in the Atp11bKO rat SVD model, with subsequent validation in human SVD tissue: 1) describe intracellular vesicular organelle function in endothelial cells in SVD, 2) determine PS/PE distribution in endothelial membranes and their action on intracellular vesicular organelle function and 3) examine if manipulation of lysosomal function and autophagy ameliorates endothelial dysfunction. PHOS-SVD interdisciplinary approach, integrating chemistry, super-resolution imagin
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the novelty, innovation potential and advance beyond the state of the art for 'Reinventing Energy Efficiency in Communication Networks' (RENEW).

assistant: **Innovation**

To this day, communications engineering has closely followed the seminal guidelines developed by Claude E. Shannon in 1948, which were mostly influenced by the telephone network of those days. The widespread use of mobile communications and the advent of machine-to-machine communications nowadays entail an exponential increase in data rates and the available models are no longer sufficient to design power-efficient, low-latency, high-speed communication systems. The overarching aim of RENEW is to further increase the data rates of the global telecommunication network while, at the same time, addressing its non-negligible environmental impact. By fundamentally revisiting the transceiver processing algorithms of the core parts of the communication network, RENEW has the potential to overcome the limitations of current design methodologies and to significantly reduce the complexity and energy consumption of the network. Capitalising on cutting-edge results in the fields of machine learning, reinforcement learning, optimisation techniques and neuromorphic computing, RENEW will reinvent the design of communication transmitters and receivers by introducing sparsely connected atomic neural blocks that realise highly parallelisable transceivers guaranteeing high throughputs with low energy consumption. RENEW will explore novel concepts for extremely energy efficient receivers based on spiking neural networks, promising efficiency gains by multiple orders of magnitude. The viability of the RENEW concepts will be demonstrated in applications of high relevance such as high-speed optical communication networks or low-power IoT applications. My industrial experience designing high-speed optical communications, together with my background in coding and communication theory as well as
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Compose a compelling abstract for 'Assembly, maintenance and novel potential drug targets of the synapse (SYNAPTOGENET)' demonstrating excellence, impact and implementation quality for a Fifth Framework call.

assistant: **Abstract**

Synapses are key elements for neuronal communication in the brain. Many synaptic proteins are targets for neuropharmaceuticals as well as neurotoxins and street drugs. Synaptic dysfunction is associated with various neurological disorders. The pivotal objectives of this study are to gain precise insight into processes of synaptic assembly and function, to understand path mechanisms underlying synaptic dysfunction and to discover novel targets for neuropharmaceuticals. The skills of the partners in molecular biology, genetics (including advanced trans-genie technologies in mouse and fly), bio informatics, biochemistry, electro-physiology, cell biology and functional anatomy will be combined to: study mechanisms of synapse assembly, identify genes involved in acquisition of synaptic competence (i.e. the ability to form synapses), analyse molecular mechanisms of transmitter release, and find and validate new potential drug targets.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Write a project proposal abstract for 'Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.' to be submitted under Horizon 2020.

assistant: **Abstract**

Based on these principles, we developed our first marketing solution C.A.P. (Connecting Ad-Impressions with Purchase): A novel digital marketing channel installed in grocery stores. The intelligent system ensures that shoppers see relevant content during their purchase decisions. C.A.P. connects the seen content with a shopper’s transactional data, enabling unique big data analyses to measure the advertising effectiveness. After several years of development, C.A.P. was launched mid-2018 in Germany and since then, the system’s market demand (profitability), technical functionality and advertising effect hass been continuously monitored. 100% of the store managers want to keep the system. Various brands have run a campaign on C.A.P. and are enthusiastic about its impact and respective analytical insights – therefore our customers were willing to pay prices which are several times higher than average TV advertising. This highlights the importance to quickly build up reach.
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the novelty, innovation potential and advance beyond the state of the art for 'DISRUPTIVE GPCR LEAD DISCOVERY PLATFORM DELIVERING NEW AND SAFER THERAPEUTICS' (PICARD).

assistant: **Innovation**

InterAx Biotech, a Swiss company and spin-off from the ETH Zürich and the Paul Scherrer Institute, has built PICARD, an innovative and unique lead discovery platform for the design and selection of better drug candidates. PICARD combines a systems biology approach with experimental data and uses artificial intelligence methods to design novel compounds with the desired properties. This holistic approach differentiates PICARD from technologies now used in the pharmaceutical industry. Our systems biology approach provides PICARD with in vivo predictability, dramatically reducing the need for animal testing (60-80%) and increasing the probability of success of drug candidates in clinical trials. At the moment, the success rate in clinical trials is lower than 12%. This produces sizeable costs (€2.3 billion) and extremely long time to market (15 years or longer) in drug development.We offer custom-designed PICARD services to pharmaceutical and biotech companies that are outsourcing key stages of their drug discovery process. PICARD remarkably increases the efficiency of the drug discovery process, offering our customers economic savings of at least €150.7 million per developed drug and a reduction of time to market to 10 years.PICARD focuses on G-Protein Coupled Receptors (GPCRs), which are the target of 40% of the developed drugs. However, >70% of the pharmacologically relevant GPCRs are yet to be exploited, which creates an untapped global market opportunity of €71.2 billion. We intend to acquire, in seven years, 1-2% of the European and US available markets (€940 million). To achieve this goal, we have designed a business model in which PICARD is offered at increasing levels of support, investment and risks for our customers: service projects, pilot projects and long ter
system: You are an expert grant writer specializing in European Union research funding proposals. You write compelling, well-structured proposal sections that demonstrate excellence, impact, and implementation quality, using precise EU terminology and following best practices for Horizon Europe, Horizon 2020, and earlier framework programmes.

user: Describe the novelty, innovation potential and advance beyond the state of the art for 'Discovery of bioactive natural compounds from Traditional Chinese Medicines (TCMs) used against Cardiovascular Disease (CVD)' (TCMs).

assistant: **Innovation**

Major aim of TCM-VASC is the discovery and characterisation of bioactive natural compounds from medicinal plants successfully used for centuries in Traditional Chinese Medicine (TCM) against Cardiovascular Disease (CVD). The discovery of such compounds is of great interest since CVD is the number one cause of mortality and morbidity worldwide. For many TCMs beneficial action on CVD are documented, but their mechanisms of action and the responsible bioactive compounds are largely unknown. The identification of bioactive compounds that are responsible for the efficacy of TCMs will have a big social impact since it will contribute to TCM standardization, resulting in improved effectiveness and safety benefiting patients and consumers. Furthermore, such compounds might be interesting leads for the development of new pharmaceuticals or could be used as dietary supplements with health-promoting or disease-preventing properties. To achieve TCM-VASC´s objectives, medicinal plants traditionally used in China for the treatment of CVD will be selected based on the expertise of the Applicant (Dr. Rongxia Liu) and the Return Host (Professor De-an Guo, Director of Shanghai Research Centre for TCM Modernization). For identification and characterization of the bioactive compounds TCM-VASC will apply a combination of phytochemical methods that will be established and used by the Applicant, with a set of cell-based assays relevant for CVD that are available in the lab of the Incoming Host (Professor Verena M. Dirsch, Head of the Department of Pharmacognosy at the University of Vienna). The identified/isolated pure compounds exhibiting activity in the cell models will be further investigated, to obtain indications for their mechanism of action. Several of the most promising compounds will